About us

 

Neurochlore, a Marseille based biotechnology company, aims to develop a treatment for Autism Spectrum Disorders.


Created in 2011, Neurochlore is dedicated to the research and development of innovative treatments to help people with neurodevelopmental disorders, and especially Autism Spectrum Disorders.

This company has moved from proof of concept to the test phase of a drug candidate, bumetanide, in less than 10 years. It initiated with its partner, Les Laboratoires Servier, an international clinical trial which could result, in 2022, to the marketing of the first drug treatment for Autism Spectrum Disorders.


We have given ourselves 10 years to develop the first treatment for Autism Spectrum Disorders. Patients are waiting for us, we will put all our efforts into developing a treatment that could improve their lives.

Yehezkel Ben-Ari, Neurochlore President


People

 

Yehezkel Ben-Ari

Yehezkel Ben-Ari, PhD

President and Co-founder

Read Dr. Ben-Ari’s blog

Constance Hammond

Constance Hammond, PhD

General Director

Denis Ravel

Denis Ravel, PhD

Development Director

Diana Ferrari

Diana Ferrari, PhD

Senior Researcher and Project Manager

Morgane Chiesa

Morgane Chiesa, PhD

Junior Researcher


Robin Cloarec

Robin Cloarec, PhD

Researcher

Amandine Dufour

Amandine Dufour, PhD

Researcher

Camille Dumon

Camille Dumon, PhD

Researcher

Laurie-Anne Gouty-Colomer

Laurie-Anne Gouty-Colomer, PhD

Researcher

Sanaz Eftekhari

Sanaz Eftekhari, PhD

Researcher


Alexandre Pons-Bennaceur, PhD

Junior Researcher

Hamed Rabiei, PhD

Researcher

Baptiste Riffault

Baptiste Riffault, PhD

Researcher

Anice Moumen, PhD

Lab Manager

Maxime Billon-Grand

Maxime Billon-Grand

Senior Technician


Magali Conesa

Magali Conesa, PhD

Administrative Manager

Anaïs Lemineur

Task Officer


› Yehezkel Ben-Ari, PhD

President and Co-founder

Eric Lemonnier, MD, PhD

Co-founder

Nouchine Hadjikhani, MD, PhD

Co-founder

Wendy Chung, MD

Andy Gyenes, MS

Pasko Rakic, MD, PhD

Professor of Neurobiology and Neurology Chairman, Department of Neurobiology, Yale University Director, Kavli Institute of Neuroscience, Yale University

Charles Nelson, PhD

Professor of Pediatrics Harvard Medical School, Boston Children’s Hospital, Director of Research, Developmental Medicine Center

Gordon Fishell, PhD

Professor of Neurobiology Harvard Medical School, Professor of Neurobiology, The Stanley Center, Broad Institute

Gyorgy Buzsaki, MD, PhD

Professor, Department of Neurology NYU Langone Medical Center Neuroscience Institute, Biggs Professor of Neuroscience, Department of Neuroscience and Physiology

Nicholas Spitzer, PhD

Professor, Division of Biological Sciences, UC San Diego Health Sciences, Atkinson Family Chair

Yehezkel Ben-Ari

Yehezkel Ben-Ari, PhD

President, Acting Chief Executive Officer and Co-founder

Physiologist and biophysicist, Yehezkel Ben-Ari (YBA) has made many seminal discoveries on brain developmental sequences, infantile and adult epilepsies, the mechanisms of migration disorders and anoxic insults etc. These include the excitatory /inhibitory shift of GABA actions during brain development, the excitatory actions of GABA in epilepsies and other brain disorders, the formation of aberrant synapses in the epileptic brain, the maturation of neuronal and network activities and associated sequences. Author of 500 publications and amongst the highest quoted neuroscientists, Yehezkel Ben-Ari has received many prizes including the US and European Epilepsy research highest prizes and the INSERM 2009 Biomedical prize for his contributions to brain development. He has directed an INSERM unit for over 20 years, founded INMED and directed it since its foundation until September 2011. Yehezkel Ben-Ari has recently suggested two major concepts including the “check point“ and “Neuroarcheology” concepts that suggest that neuronal activity controls the correct implementation of developmental sequences and a failed implementation of the program leads to delayed maturation of electrical properties of misplaced and misconnected neurons that in an adult brain will conserve immature features. This paves the way to novel therapeutic strategies based on the use of agents that specifically block immature channels and transporters. This strategy has been used successfully with our diuretic approach to treat ASD and epilepsies.


Eric Lemonnier

Eric Lemonnier, MD, PhD

Co-founder

Resident in psychiatry (Paris, France) and then clinical head in child psychiatry (Brest, France), Eric Lemonnier is a hospital practitioner and has obtained a Master in neurosciences (Paris V). He is a member of the Neurosciences Laboratory of the Regional University Hospital Center (RUHC) of Brest since its creation, conducting activities of research and thesis supervision. He directed the Autism Resource Center of Brittany from its creation in 2000 to 2013. Since 2014, he has been responsible of the Autism Expert Center of Limousin, France. During his entire career, he led a double activity – clinical and research – that allowed him to be contacted to join the scientific committee of several associations (ARAPI, APESA, AFTR, autisme suisse romande). His research has led to more than 40 publications in peer-reviewed journals including more than 20 in Anglo-Saxon journals. Since 2008, he has been working with Yehezkel Ben-Ari on the development of a novel therapeutic approach for autism.


Nouchine Hadjikhani

Nouchine Hadjikhani, MD, PhD

Co-founder

Nouchine Hadjikhani is Associate Professor of Radiology at Harvard Medical School (Boston, USA) and Professor of Experimental Child and Adolescent Psychiatry at the University of Gothenburg (Sweden). She has over 20 years of experience in brain imaging, with over 100 publications in renowned scientific journals. She graduated in Medicine (University of Lausanne, Switzerland) and Neurosciences (University of Tilburg, Holland). After a post-doctorate at the Karolinska Institute in Sweden, she continued her career at the Martinos Center for Biomedical Imaging in Boston. She has been working on autism since 2000, using brain imaging and other behavioral measures like eye tracking. From 2006 to 2012 she also directed a research laboratory on autism and social cognition at the Ecole Polytechnique Fédérale de Lausanne thanks to a chair from the Swiss National Science Foundation and in 2015 received the LifeWatch prize for her work on autism.